[go: up one dir, main page]

MX2010004289A - Productos quimioterapeuticos cristalinos. - Google Patents

Productos quimioterapeuticos cristalinos.

Info

Publication number
MX2010004289A
MX2010004289A MX2010004289A MX2010004289A MX2010004289A MX 2010004289 A MX2010004289 A MX 2010004289A MX 2010004289 A MX2010004289 A MX 2010004289A MX 2010004289 A MX2010004289 A MX 2010004289A MX 2010004289 A MX2010004289 A MX 2010004289A
Authority
MX
Mexico
Prior art keywords
chemotherapeutic
crystalline
ways
crystalline chemotherapeutic
methylpheny
Prior art date
Application number
MX2010004289A
Other languages
English (en)
Inventor
Michael J Rozema
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010004289A publication Critical patent/MX2010004289A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Forma cristalina 1 de N-(4-(3-amino-1H-indazol-4-il)fenil)-N'-(2- fluoro-5-metilfenil)urea toluenato, maneras para elaborarla y formas de usarla.
MX2010004289A 2007-10-19 2008-10-16 Productos quimioterapeuticos cristalinos. MX2010004289A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98124307P 2007-10-19 2007-10-19
PCT/US2008/080066 WO2009052229A1 (en) 2007-10-19 2008-10-16 Crystalline chemotherapeutic

Publications (1)

Publication Number Publication Date
MX2010004289A true MX2010004289A (es) 2010-04-30

Family

ID=40242659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004289A MX2010004289A (es) 2007-10-19 2008-10-16 Productos quimioterapeuticos cristalinos.

Country Status (20)

Country Link
US (1) US7943782B2 (es)
EP (1) EP2195297A1 (es)
JP (1) JP2011500706A (es)
KR (1) KR20100102098A (es)
CN (1) CN101827823B (es)
AU (1) AU2008312532A1 (es)
BR (1) BRPI0818343A2 (es)
CA (1) CA2699353A1 (es)
CO (1) CO6280483A2 (es)
CR (1) CR11386A (es)
DO (1) DOP2010000116A (es)
GT (1) GT201000101A (es)
MX (1) MX2010004289A (es)
MY (1) MY153098A (es)
PA (1) PA8800501A1 (es)
RU (1) RU2010119917A (es)
SG (1) SG185326A1 (es)
UA (1) UA99487C2 (es)
WO (1) WO2009052229A1 (es)
ZA (1) ZA201002092B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140031769A1 (en) 2010-11-19 2014-01-30 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc DISPOSAL OF SMALL MOLECULES THROUGH AN IMPLANTABLE THERAPEUTIC DEVICE
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CA2957548A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003232113A1 (en) * 2002-05-10 2003-11-11 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
EP1620101A4 (en) * 2003-05-08 2008-07-09 Ivax Pharmaceuticals Sro POLYMORPHS OF CABERGOLIN
BRPI0410745A (pt) * 2003-05-22 2006-06-27 Abbott Lab inibidores de indazol, benzisoxazol e benzisotiazol quinase
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
DE102005033100B3 (de) * 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Neues 1,4-Benzothiazepin-1,1-Dioxidderivat mit verbesserten Eigenschaften, diese Verbindung enthaltene Arzneimittel und Verfahren zu deren Herstellung
WO2007015569A1 (ja) * 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
US9006240B2 (en) * 2005-08-02 2015-04-14 Eisai R&D Management Co., Ltd. Method for assay on the effect of vascularization inhibitor
EP1959926A1 (en) 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
EP1962803A1 (en) * 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP1984342A2 (en) * 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
ZA201002092B (en) 2011-11-30
JP2011500706A (ja) 2011-01-06
US7943782B2 (en) 2011-05-17
GT201000101A (es) 2012-03-26
EP2195297A1 (en) 2010-06-16
CR11386A (es) 2010-08-18
DOP2010000116A (es) 2010-05-31
CN101827823A (zh) 2010-09-08
PA8800501A1 (es) 2009-05-15
CO6280483A2 (es) 2011-05-20
WO2009052229A1 (en) 2009-04-23
BRPI0818343A2 (pt) 2017-05-23
SG185326A1 (en) 2012-11-29
RU2010119917A (ru) 2011-11-27
US20090105486A1 (en) 2009-04-23
KR20100102098A (ko) 2010-09-20
CN101827823B (zh) 2012-10-03
MY153098A (en) 2014-12-31
UA99487C2 (xx) 2012-08-27
CA2699353A1 (en) 2009-04-23
AU2008312532A1 (en) 2009-04-23

Similar Documents

Publication Publication Date Title
DE602008000754D1 (de) Tropanverbindungen
ZA200700084B (en) 2,4-DI(aminopheyl) pyrimidines AS PKL inhibitors
TW200615264A (en) N-(ortho-phenyl)-1-methyl-3-difluoromethylpyrazole-4-carboxanilides and their use as fungicides
SI2201018T1 (sl) Trdne oblike, ki obsegajo N-(5-terc.butil-izoksazol-3-il)-N'-(4-Y7-(2- morfolin-4-il-etoksi)imidazoY2,1-B"Y 1,3"benzotiazol-2-ilfenil)sečnina, njihove sestave in uporabe z njimi
PL2152701T3 (pl) Związki fenyloaminopirymidyny i ich zastosowania
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
TW200745028A (en) Novel sulphonylpyrroles
MX2007005932A (es) 1-alquinil-2-ariloxialquilamidas y su uso como fungicidas.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
IL183666A0 (en) Amide prodrug of gemcitabine, compositions and use thereof
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
TW200745027A (en) Novel sulphonylpyrroles
DE502008001158D1 (en) Benzimidazolderivate
SMT201300072B (it) Sale difosfato di N-[6-(cis-2,6-dimetilmorfolin-4-il)piridin-3-il]-2-metil-4'-(tri-fluorometossi)[1,1'-bifenil]-3-carbossammide
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
MX2010004289A (es) Productos quimioterapeuticos cristalinos.
PL1912644T3 (pl) Pochodne n-(aryloalkilo)-1H-pirolopirydyno-2-karboksyamidów, ich wytwarzanie i ich zastosowanie do leczenia
MX2010004290A (es) Productos quimioterapeuticos cristalinos.
MX2010004287A (es) Productos quimioterapeuticos cristalinos.
CL2008003091A1 (es) Forma cristalina 1 de etanolato de n-(4-(3-amino-1h-indazol-4il)fenil)-n-(2-fluoro-5-metilfenil)urea. 1/4; composicion farmaceutica; y uso en el tratamiento de cancer en un mamifero.
UA99746C2 (ru) Кристаллическое химиотерапевтическое средство на основе индазола
EP1900735A4 (en) PYRIDAZINYLAMINE DERIVATIVES, USE OF DERIVATIVES IN THE PREPARATION OF PICORNAVIRUS INHIBITORS
GB0514743D0 (en) Salt
DE602007005878D1 (de) Verwendung von 1,2-Dihydroperillaldehyd in Geschmacksanwendungen

Legal Events

Date Code Title Description
FG Grant or registration